Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:clinicalTrials.gov_Identifier |
NCT00829166
|
| gptkbp:conditionStudied |
HER2-positive metastatic breast cancer
|
| gptkbp:endPoint |
overall survival
progression-free survival |
| https://www.w3.org/2000/01/rdf-schema#label |
EMILIA trial
|
| gptkbp:location |
international
|
| gptkbp:participants |
991
|
| gptkbp:period |
Phase III
|
| gptkbp:publicationDate |
2012
|
| gptkbp:publishedIn |
gptkb:The_New_England_Journal_of_Medicine
|
| gptkbp:result |
trastuzumab emtansine improved progression-free survival
trastuzumab emtansine improved overall survival |
| gptkbp:sponsor |
gptkb:Genentech
F. Hoffmann-La Roche Ltd. |
| gptkbp:startDate |
2009
|
| gptkbp:studiedBy |
gptkb:capecitabine
gptkb:lapatinib gptkb:trastuzumab_emtansine |
| gptkbp:bfsParent |
gptkb:HER2-positive_breast_cancer
|
| gptkbp:bfsLayer |
7
|